1. The two coin sides of bacterial extracellular membrane nanovesicles: atherosclerosis trigger or remedy
- Author
-
Konstantin A. Lusta, Alexey V. Churov, Dmitry F. Beloyartsev, Alexander L. Golovyuk, Arthur A. Lee, Vasily N. Sukhorukov, and Alexander N. Orekhov
- Subjects
Bacterial extracellular membrane nanovesicles ,Atherosclerosis ,Cardiovascular disease ,Anti-atherosclerotic therapy ,Nanomedicine ,Targeted drug delivery ,Materials of engineering and construction. Mechanics of materials ,TA401-492 - Abstract
Abstract Among the numerous driving forces that cause the atherosclerotic cardiovascular disease (ASCVD), pathogenic bacterial extracellular membrane nanovesicles (BEMNs) containing toxins and virulence factors appear to be the key trigger of inflammation and atherogenesis, the major processes involved in the pathogenesis of ASCVD. Since BEMNs are the carriers of nanosized biomolecules to distant sites, they are now being considered as a novel drug delivery system. Nowadays, many therapeutic strategies are used to treat ASCVD. However, the conventional anti-atherosclerotic therapies are not effective enough. This primarily due to the inefficiency of non-targeted drug delivery systems to tissue affected areas, which, in turn, leads to numerous side effects, as well as faulty pharmacokinetics. In this regard, nanomedicine methods using nanoparticles (NPs) as targeted drug delivery vehicles proved to be extremely useful. Bioengineered BEMNs equipped with disease-specific ligand moieties and loaded with corresponding drugs represent a promising tool in nanomedicine, which can be used as a novel drug delivery system for a successful therapy of ASCVD. In this review, we outline the involvement of pathogenic BEMNs in the triggering of ASCVD, the conventional therapeutic strategies for the treatment of ASCVD, and the recent trends in nanomedicine using BEMNs and NPs as a vehicle for targeted drug delivery.
- Published
- 2024
- Full Text
- View/download PDF